Twist Bioscience Corporation (TWST)
After hours:
| Previous close | 36.99 |
| Open | 37.01 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 1200 |
| Day's range | 35.47 - 37.89 |
| 52-week range | 25.88 - 139.99 |
| Volume | |
| Avg. volume | 973,440 |
| Market cap | 2.105B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.72 |
| Earnings date | 04 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 47.17 |
- Business Wire
Twist Bioscience to Present at the 2022 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on Monday, May 23 at 9:15 a.m. Eastern Time in New York.
- GlobeNewswire
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our N
- Simply Wall St.
Investors one-year losses grow to 71% as the stock sheds US$149m this past week
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
